Endocrine Abstracts

Somapacitan is a long-acting growth hormone (GH) derivative designed for once-weekly subcutaneous administration. Correct assessment of insulin-like growth factor-I (IGF-I) levels is essential during treatment of GH deficiency (GHD) and must account for fluctuations over a dosing interval. We evaluated whether reliable estimates of weekly mean and peak IGF-I could be obtained from a single IGF-I sample. A population pharmacokinetic/pharmacodynamic model was available from phar...